| Chemotherapy Details | Neoadjuvant Chemotherapy (16) | Primary Cytoreductive surgery (28) |
| 1. Chemotherapy regimen | ||
| Carboplatin/Paclitaxel | 14(87.7%) | 16(57.1%) |
| Cisplatin/Doxorubicin | 1(06.3%) | 8 (28.6%) |
| Carboplatin (single agent) | 0 | 1 (03.6%) |
| Carboplatin /Paclitaxel followed by Cisplatin/Doxorubicin | 1(06.3%) | 2 (07.1%) |
| Declined Chemotherapy | 0 | 1 (03.6%) |
| 2. Chemotherapy associated Complications (grade 1 or more) | ||
| Neuropathy | 3 (18.7%) | 6 (21.4%) |
| Tinnitus | 1 (06.2%) | 0 |
| 3. Response to chemotherapy | ||
| Complete response | 0 | |
| Good partial response | 7 (43.8%) | |
| Partial response | 8 (18.7%) | |
| Poor partial response | 1 (06.3%) | |
| 4. External Beam Radiotherapy (EBRT) | 8 (50%) | 22 (78.6%) |